GermanyGermany

Arteriosclerosis switch

12.09.2009

Bad Nauheim – German researchers have discovered a way to prevent arteriosclerosis at an early stage. Transgenic mice that did not express miRNAs miR143 and145 showed the pathological remodeling of their blood vessels during the development of smooth muscle cells (SMCs) typical for arteriosclerosis (J. Clin. Invest., doi 10.1172/JCI38864). The fraction of contractile vessel muscle cells (VSMCs) was reduced in favour of VSMCs that showed the so-called synthetic phenotype, with reduced contractility and signs of inflammation.After carrying out a proteome analysis, the team headed by Thomas Braun (Max-Planck Institute of Heart and Lung Research) identified angiotensin converting enzyme (ACE) as the key protein regulated by the miRNAs. Inhibition of ACE or the AT1-receptor partially reversed the vascular dysfunction, revealing a means of attenuating arteriosclerotic remodeling.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/arteriosclerosis-switch.html

Image Gallery

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

    FLOP

      No liability assumed, Date: 18.04.2014

      Current issue

      All issues

      Product of the week

      Products

      Events

      All Events

      Partner-Events

      München

      BioVaria 2014

      Frankfurt am Main

      7th DVFA Life Science Conference

      White Paper